Tyler A. Longmire
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Galectins and Cancer Biology, Peptidase Inhibition and Analysis, CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells(2012)388 cited
- → Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors(2021)337 cited
- → Excision of Reprogramming Transgenes Improves the Differentiation Potential of iPS Cells Generated with a Single Excisable Vector(2009)268 cited
- → Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies(2022)149 cited
- → Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)(2019)85 cited
- → Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment(2021)59 cited
- → Mouse ES and iPS cells can form similar definitive endoderm despite differences in imprinted genes(2011)51 cited
- → Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies(2019)43 cited
- → Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor(2022)41 cited
- → Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy(2019)29 cited